NASDAQ:NBRV Nabriva Therapeutics - NBRV Stock Forecast, Price & News Notice: Trading of Nabriva Therapeutics halted at 09:35 AM EST due to "LULD pause". Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nabriva Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $1.68 -0.07 (-4.13%) (As of 03/27/2023 03:28 PM ET) Add Compare Share Share Today's Range$1.26▼$1.8150-Day Range$1.49▼$1.9052-Week Range$1.22▼$12.80Volume44,027 shsAverage Volume42,488 shsMarket Capitalization$51.40 millionP/E RatioN/ADividend YieldN/APrice Target$50.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Nabriva Therapeutics MarketRank™ ForecastAnalyst RatingReduce1.00 Rating ScoreUpside/Downside2,780.2% Upside$50.00 Price TargetShort InterestHealthy0.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($17.37) to ($8.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 starsMedical Sector668th out of 995 stocksPharmaceutical Preparations Industry322nd out of 482 stocks 2.5 Analyst's Opinion Consensus RatingNabriva Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $50.00, Nabriva Therapeutics has a forecasted upside of 2,780.2% from its current price of $1.74.Amount of Analyst CoverageNabriva Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.92% of the float of Nabriva Therapeutics has been sold short.Short Interest Ratio / Days to CoverNabriva Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nabriva Therapeutics has recently decreased by 10.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNabriva Therapeutics does not currently pay a dividend.Dividend GrowthNabriva Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NBRV. Previous Next 2.0 News and Social Media Coverage News SentimentNabriva Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nabriva Therapeutics this week, compared to 1 article on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nabriva Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.63% of the stock of Nabriva Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.23% of the stock of Nabriva Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Nabriva Therapeutics are expected to grow in the coming year, from ($17.37) to ($8.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nabriva Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nabriva Therapeutics is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNabriva Therapeutics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nabriva Therapeutics (NASDAQ:NBRV) StockNabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.Read More Receive NBRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBRV Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comNabriva Therapeutics (NASDAQ:NBRV) Now Covered by Analysts at StockNews.comMarch 17, 2023 | americanbankingnews.comNabriva Therapeutics (NASDAQ:NBRV) Earns Hold Rating from Analysts at StockNews.comMarch 27, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 28, 2023 | marketwatch.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 25, 2023 | seekingalpha.comNBRV Nabriva Therapeutics plcJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Provides Corporate UpdateNovember 28, 2022 | marketwatch.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | markets.businessinsider.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisMarch 27, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.November 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | bizjournals.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | seekingalpha.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | finance.yahoo.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 10, 2022 | finance.yahoo.comMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | technews.tmcnet.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 10, 2022 | finance.yahoo.comNabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNovember 7, 2022 | finance.yahoo.comNabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022September 15, 2022 | finance.yahoo.comNabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitSeptember 14, 2022 | finance.yahoo.comAll You Need to Know About Nabriva Therapeutics AG (NBRV) Rating Upgrade to BuySeptember 6, 2022 | finance.yahoo.comNabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 12, 2022 | marketwatch.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA(R) (lefamulin) in Adult Patients with Cystic FibrosisAugust 11, 2022 | finance.yahoo.comNabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisAugust 4, 2022 | seekingalpha.comNabriva Therapeutics plc (NBRV) CEO Ted Schroeder on Q2 2022 Results - Earnings Call TranscriptAugust 3, 2022 | finance.yahoo.comNabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateJuly 20, 2022 | finance.yahoo.comNabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nabriva Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NBRV Company Calendar Last Earnings5/06/2021Today3/27/2023Next Earnings (Estimated)4/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBRV CUSIPN/A CIK1641640 Webwww.nabriva.com Phone(531) 649-2000Fax610-816-6639Employees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$50.00 High Stock Price Forecast$50.00 Low Stock Price Forecast$50.00 Forecasted Upside/Downside+2,930.3%Consensus RatingReduce Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($19.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,450,000.00 Net Margins-133.25% Pretax Margin-129.87% Return on Equity-120.02% Return on Assets-76.01% Debt Debt-to-Equity Ratio0.02 Current Ratio2.20 Quick Ratio1.40 Sales & Book Value Annual Sales$28.90 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book0.70Miscellaneous Outstanding Shares30,640,000Free Float30,140,000Market Cap$50.56 million OptionableOptionable Beta1.53 Key ExecutivesJohn Christopher NaftzgerCEO, Secretary & General CounselDan DolanChief Financial OfficerChristine Guico-PabiaChief Medical OfficerJodi VanDerveerSenior Vice President & Head-Human ResourcesKim AndersonInvestor & Media ContactKey CompetitorsSpruce BiosciencesNASDAQ:SPRBBolt BiotherapeuticsNASDAQ:BOLTHepion PharmaceuticalsNASDAQ:HEPAViracta TherapeuticsNASDAQ:VIRXHomology MedicinesNASDAQ:FIXXView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 22,294 shares on 2/14/2023Ownership: 0.073%Charles A Rowland JrSold 8,496 sharesTotal: $1,444.32 ($0.17/share)View All Insider TransactionsView All Institutional Transactions NBRV Stock - Frequently Asked Questions Should I buy or sell Nabriva Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street equities research analysts is that investors should "sell" NBRV shares. View NBRV analyst ratings or view top-rated stocks. What is Nabriva Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month price objectives for Nabriva Therapeutics' shares. Their NBRV share price forecasts range from $50.00 to $50.00. On average, they expect the company's stock price to reach $50.00 in the next year. This suggests a possible upside of 2,662.4% from the stock's current price. View analysts price targets for NBRV or view top-rated stocks among Wall Street analysts. How have NBRV shares performed in 2023? Nabriva Therapeutics' stock was trading at $1.89 at the start of the year. Since then, NBRV stock has decreased by 4.2% and is now trading at $1.81. View the best growth stocks for 2023 here. When is Nabriva Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023. View our NBRV earnings forecast. How were Nabriva Therapeutics' earnings last quarter? Nabriva Therapeutics plc (NASDAQ:NBRV) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($13.25) earnings per share for the quarter, topping analysts' consensus estimates of ($16.75) by $3.50. The biotechnology company earned $2.53 million during the quarter, compared to the consensus estimate of $2.25 million. Nabriva Therapeutics had a negative trailing twelve-month return on equity of 120.02% and a negative net margin of 133.25%. Read the conference call transcript. When did Nabriva Therapeutics' stock split? Shares of Nabriva Therapeutics reverse split before market open on Friday, September 16th 2022. The 1-25 reverse split was announced on Friday, September 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Nabriva Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nabriva Therapeutics investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Agile Therapeutics (AGRX), Dynavax Technologies (DVAX), Acasti Pharma (ACST), Amarin (AMRN), AcelRx Pharmaceuticals (ACRX), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and Heat Biologics (HTBX). What is Nabriva Therapeutics' stock symbol? Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV." Who are Nabriva Therapeutics' major shareholders? Nabriva Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Susquehanna International Group LLP (0.07%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Charles A Rowland Jr, Colin Md Broom, J Christopher Naftzger, Stephen W Webster, Theodore R Schroeder and Theodore R Schroeder. View institutional ownership trends. How do I buy shares of Nabriva Therapeutics? Shares of NBRV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nabriva Therapeutics' stock price today? One share of NBRV stock can currently be purchased for approximately $1.81. How much money does Nabriva Therapeutics make? Nabriva Therapeutics (NASDAQ:NBRV) has a market capitalization of $55.46 million and generates $28.90 million in revenue each year. The biotechnology company earns $-49,450,000.00 in net income (profit) each year or ($19.71) on an earnings per share basis. How can I contact Nabriva Therapeutics? Nabriva Therapeutics' mailing address is 25-28 NORTH WALL QUAY IFSC, DUBLIN L2, 19406. The official website for the company is www.nabriva.com. The biotechnology company can be reached via phone at (531) 649-2000, via email at david.garrett@nabriva.com, or via fax at 610-816-6639. This page (NASDAQ:NBRV) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.